By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617

Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit

Key Statistics

Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax Corp.  Antibody phage display

Company News
Biogen (BIIB) To Highlight Broad Research Commitment To MS Care At ECTRIMS Congress, Including New TECFIDERA Data Demonstrating Importance Of Early Treatment 10/1/2015 12:38:25 PM
Genomics PLC Signs Collaboration Agreement With Biogen (BIIB) 10/1/2015 11:09:22 AM
Biogen (BIIB) And Sobi Receive Positive Opinion From CHMP For ELOCTA (Rfviiifc) For The Treatment Of Hemophilia A 9/25/2015 10:41:57 AM
Biogen (BIIB) And Swedish Orphan Biovitrum Receive Positive Opinion From CHMP For Elocta (Rfviiifc) For The Treatment Of Hemophilia A 9/25/2015 9:07:38 AM
Biogen (BIIB) To Report Third Quarter 2015 Financial Results On October 21, 2015 9/23/2015 10:53:26 AM
Biogen (BIIB) Wants to Go Beyond Drugs, Eyes Medtech 9/23/2015 6:50:35 AM
BioMotiv And Biogen (BIIB) Form Strategic Partnership In Neuroscience 9/22/2015 1:20:24 PM
Celgene (CELG), Amgen (AMGN), Biogen (BIIB): Why Big-Cap Biotech Short Interest Is Up 9/14/2015 8:50:50 AM
Biogen (BIIB) Named The Global Biotechnology Industry Leader On Dow Jones Sustainability World Index For Second Consecutive Year 9/11/2015 7:33:58 AM
Biogen (BIIB) To Present At The Morgan Stanley Global Healthcare Conference 9/9/2015 10:42:42 AM